A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.
Lyman has emerged as an important voice about biosimilars and their potential for corralling cancer costs. It's personal because Lyman is all too aware of how the price of medications can ruin patients financially. We need more biosimilars on the market, he contends.